微小RNA在癫痫中的病理生理作用与临床转化前景
该综述指出颞叶癫痫涉及基因表达网络的大规模改变,微小RNA(miRNA)通过调控多个蛋白表达成为关键调控机制与治疗靶点。近五年研究在患者海马和动物模型中发现miRNA水平变化,功能研究显示调控miR-134、miR-128等可影响癫痫发作,血液miRNA差异提示诊断生物标志物潜力,但临床转化仍面临递送与脱靶效应等挑战。
要点
- miRNA通过降低mRNA稳定性和翻译调控多个癫痫相关基因网络。
- 动物模型中沉默miR-134有抗癫痫作用,敲除miR-128致致死性癫痫。
- 患者血液 circulating miRNA 差异提示诊断生物标志物潜力。
核心结论
- miRNA是颞叶癫痫基因网络调控的关键机制和潜在治疗靶点。
- 近期功能研究识别了九个影响癫痫发作或海马病理的新miRNA。
- miRNA距临床转化尚有递送、脱靶效应和证据重复等挑战。
研究设计与样本
- 综述类文章,检索范围未在摘要中明确报告。
主要发现
- 近五年研究在颞叶癫痫患者海马和动物模型神经组织中发现miRNA水平改变。
- 用反义寡核苷酸沉默脑特异性miR-134在动物模型中产生强效抗癫痫作用。
- miR-128基因缺失在小鼠中产生致死性癫痫。
- 近18个月功能研究识别九个新miRNA影响癫痫发作或海马病理,靶点包括转录因子、神经递质信号组分和神经炎症调节因子。
- 癫痫患者血液中循环miRNA数量存在差异,提示诊断生物标志物潜力。
关键数值与推荐
- 沉默miR-134使用反义寡核苷酸(antagomirs)在动物模型中显示强效抗癫痫效应。
- miR-128基因缺失在小鼠中导致致死性癫痫。
- 注射模拟物(agomirs)以提高脑内miRNA水平的新方法已被测试。
- DNA甲基化研究提示miRNA水平受表观遗传调控。
临床怎么用
- 近期功能研究需重复以建立稳健证据基础。
- 需明确miRNA发挥功能的特定细胞类型和主要靶点以解释表型效应。
- 反义抑制剂或模拟物等大分子向脑内递送仍是挑战。
- miRNA多靶点效应带来意外副作用风险,需评估。
- 应探索miRNA遗传变异作为疾病易感性基础。
局限性
- 近期功能研究证据需重复验证。
- miRNA作用的特定细胞类型和主要靶点尚未明确。
- 大分子向脑内递送存在挑战。
- miRNA多靶点效应带来意外副作用风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Temporal lobe epilepsy is a common and frequently intractable seizure disorder. Its pathogenesis is thought to involve large-scale alterations to the expression of genes controlling neurotransmitter signalling, ion channels, synaptic structure, neuronal death, gliosis, and inflammation. Identification of mechanisms coordinating gene networks in patients with temporal lobe epilepsy will help to identify novel therapeutic targets and biomarkers. MicroRNAs (miRNAs) are a family of small non-coding RNAs that control the expression levels of multiple proteins by decreasing mRNA stability and translation, and could therefore be key regulatory mechanisms and therapeutic targets in epilepsy. RECENT DEVELOPMENTS: In the past 5 years, studies have found changes in miRNA levels in the hippocampus of patients with temporal lobe epilepsy and in neural tissues from animal models of epilepsy. Early functional studies showed that silencing of brain-specific miR-134 using antisense oligonucleotides (antagomirs) had potent antiseizure effects in animal models, whereas genetic deletion of miR-128 produced fatal epilepsy in mice. Levels of certain miRNAs were also found to be altered in the blood of rodents after seizures. In the past 18 months, functional studies have identified nine novel miRNAs that appear to influence seizures or hippocampal pathology. Their targets include transcription factors, neurotransmitter signalling components, and modulators of neuroinflammation. New approaches to manipulate miRNAs have been tested, including injection of mimics (agomirs) to enhance brain levels of miRNAs. Altered miRNA expression has also been reported in other types of refractory epilepsy and our understanding of how miRNA levels are controlled has grown, with studies on DNA methylation indicating epigenetic regulation. Biofluids (blood) of patients with epilepsy have shown differences in quantity of circulating miRNAs, implying diagnostic biomarker potential. WHERE NEXT?: Recent functional studies need to be replicated to build a robust evidence base. The specific cell types in which miRNAs execute their functions and their primary targets have to be identified, to fully explain the phenotypic effects of modulating miRNAs. Delivery of large molecules such as antisense inhibitors or mimics to the brain poses a challenge, and the multi-targeting effects of miRNAs create additional risks of unanticipated side effects. Potential genetic variation in miRNAs should be explored as the basis for disease susceptibility. The latest findings provide a rich source of new miRNA targets, but substantial challenges remain before their role in the pathogenesis, diagnosis, and treatment of epilepsy can be translated into clinical practice.
引用
- Henshall DC, Hamer HM, Pasterkamp RJ, et al. MicroRNAs in epilepsy: pathophysiology and clinical utility. Lancet Neurol. 2016. PMID: 27839653. doi:10.1016/S1474-4422(16)30246-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。